Eli Lilly and Company (LLY) Earnings: Quarterly Revenue, EPS and Margins
How are revenue and profit of Eli Lilly and Company developing? This page lists revenue, operating income, net income and earnings per share by quarter, taken from the company's published reports.
Eli Lilly and Company latest annual figures (FY 2025)
In the latest reported fiscal year (FY 2025), Eli Lilly and Company generated revenue of 65.18 USD bn. The largest segment is Mounjaro with 22.97 USD bn, about 33.1 % of total segment revenue. From gross margin (83.0 %) through operating margin (31.7 %) to net margin (31.7 %), the Sankey diagram shows how much of each revenue dollar remains at each stage of the income statement.
Eli Lilly and Company revenue by segment (FY 2025)
| Segment | Revenue | Share |
|---|---|---|
| Collaboration & Other Revenue | 4.22 USD bn | 6.1 % |
| Mounjaro | 22.97 USD bn | 33.1 % |
| Zepbound | 13.48 USD bn | 19.4 % |
| Trulicity | 4.28 USD bn | 6.2 % |
| Jardiance | 3.43 USD bn | 4.9 % |
| Other Cardiometabolic Health | 4.01 USD bn | 5.8 % |
| Verzenio | 5.72 USD bn | 8.3 % |
| Other Oncology | 3.65 USD bn | 5.3 % |
| Taltz | 3.56 USD bn | 5.1 % |
| Other Immunology | 1.68 USD bn | 2.4 % |
| Neuroscience | 1.39 USD bn | 2.0 % |
| Other Products | 943 USD m | 1.4 % |
Frequently asked questions about Eli Lilly and Company
When does Eli Lilly and Company report earnings?
Eli Lilly and Company publishes quarterly results four times a year. The quarters listed on this page follow the company's fiscal calendar as reported in its filings.
What was Eli Lilly and Company revenue in the last fiscal year?
Eli Lilly and Company reported revenue of 65.18 USD bn (FY 2025).
How profitable is Eli Lilly and Company?
Net margin was 31.7 % (FY 2025), meaning that share of every revenue unit remained as profit.